Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 8:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 562 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-Alcoholic Fatty Liver Clear all
Terminated Phase 2 Interventional Results available

Amlexanox for Type 2 Diabetes and Obesity

NCT01842282
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alternate Day Fasting, Exercise, and NAFLD

NCT04004403
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Alternate day fasting, Exercise
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Not applicable Interventional Results available

Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

NCT03696797
View directory record Official record
Conditions
Iron, Diabetes, Nonalcoholic Fatty Liver
Interventions
Blood Donation, Sham Blood Donation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

NCT04216589
View directory record Official record
Conditions
HIV Infections, Non-Alcoholic Fatty Liver Disease
Interventions
Semaglutide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Not applicable Interventional

Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.

NCT04579874
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation, Liver Steatoses
Interventions
LIVERFASt
Diagnostic Test
Lead sponsor
Fibronostics USA, Inc
Other
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Detroit, Michigan • St Louis, Missouri • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 3, 2026, 8:57 PM EDT
Recruiting Phase 4 Interventional

Quantifying Hepatic Mitochondrial Fluxes in Humans

NCT05305287
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

NCT04944992
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Montclair, California • Hialeah, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT03938246
View directory record Official record
Conditions
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Interventions
TVB-2640 25 mg (US), TVB-2640 50 mg (US), Placebo (US), TVB-2640 50 mg (China), Placebo (China), TVB-2640 75 mg (US)
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Chula Vista, California • Montclair, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 3, 2026, 8:57 PM EDT
Terminated Phase 1 Interventional

Study of Fish Oil to Reduce ALT Levels in Adolescents

NCT00694746
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 3, 2026, 8:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

NCT05332613
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
TRE plus SOC, SOC, TRE
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 3, 2026, 8:57 PM EDT
Recruiting No phase listed Observational

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

NCT05728697
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Interventions
Endoscopic ultrasound shear wave elastography
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 3, 2026, 8:57 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics

NCT00068094
View directory record Official record
Conditions
Fatty Liver, Hepatic Steatosis, Diabetes Mellitus, Liver Diseases
Interventions
Probiotic-containing powder
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Results available

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

NCT04897594
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-201, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 3, 2026, 8:57 PM EDT
Active, not recruiting No phase listed Observational

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

NCT04795219
View directory record Official record
Conditions
NAFLD, NAFLD-HIV, Hiv
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
8
States / cities
Tuscaloosa, Alabama • La Jolla, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 3, 2026, 8:57 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
165
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Non-cirrhotic NASH With Fibrosis

NCT05638737
View directory record Official record
Conditions
Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions
AZD4831, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Chandler, Arizona • Tucson, Arizona • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Not applicable Interventional

Ketogenic Diet in Non-alcoholic Fatty Liver Disease

NCT03784716
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic, Liver Diseases
Interventions
Ketogenic Diet, Standard Weight Loss Diet
Other
Lead sponsor
Marc Goodman
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 3, 2026, 8:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis

NCT00930384
View directory record Official record
Conditions
Psoriasis, Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

NCT06309992
View directory record Official record
Conditions
Obesity, Non-Alcoholic SteatoHepatitis (NASH)
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Fountain Valley, California • Gardena, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

NCT01975935
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT03976401
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EFX, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Huntington Park, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 3, 2026, 8:57 PM EDT
Completed Phase 2 Interventional

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT05989711
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
Pemvidutide, Placebo
Drug
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 3, 2026, 8:57 PM EDT
Recruiting Not applicable Interventional

The Olmsted NAFLD Epidemiology Study (TONES)

NCT04365855
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Interventions
Magnetic Resonance Elastography, Blood draw, Liver biopsy, Fibro Scan
Diagnostic Test · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 3, 2026, 8:57 PM EDT
Recruiting Phase 2 Interventional

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

NCT05526144
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions
Synthroid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 3, 2026, 8:57 PM EDT